EMVision Receives $2.12m R&D Tax Rebate

Key points

• EMVision Medical Devices received a $2.12m cash rebate from the R&D tax incentive program
• The rebate is for eligible R&D activities performed during the 2024 financial year
• Some R&D costs were capitalized and are expected to be eligible for rebate in subsequent claims

Full summary

EMVision Medical Devices Limited (ASX:EMV) has received a cash rebate of $2,120,568 from its R&D tax incentive claim for the financial year ending 30 June 2024. The Australian Federal Government's R&D Tax Incentive Program provides a cash refund on eligible research and development activities performed by Australian companies. Some R&D costs incurred during the 2024 financial year have been capitalized for tax purposes and are expected to be eligible expenditure for rebate in subsequent R&D tax incentive claims. The announcement was authorized for release by the Chairman and Managing Director of the Company.